Partial adherence to antihypertensive therapy fails to achieve full cardiovascular benefits in hypertensive rats

American Journal of the Medical Sciences

Volumn 335, Issue 6, 2008, Pages 420-425

  Susic, Dinko ^a,b   Krousel Wood, Marie ^b,c   Zhou, Xiaoyan ^a   Frohlich, Edward D ^a  

^a Hypertension Research Laboratory

^b OCHSNER CLINIC FOUNDATION   (United States)

^c TULANE UNIVERSITY   (United States)

Author keywords

Adherence; Cardiovascular risk; Hemodynamics; Hypertension; Medications

Indexed keywords

CANDESARTAN; N(G) NITROARGININE METHYL ESTER; ANTIHYPERTENSIVE AGENT; BENZIMIDAZOLE DERIVATIVE; TETRAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; BLOOD FLOW; BODY WEIGHT; BRAIN; CARDIOVASCULAR RISK; CONTROLLED STUDY; DRUG TREATMENT FAILURE; HEART; HEART FUNCTION; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE FUNCTION; HEMODYNAMICS; KIDNEY; MALE; MALIGNANT HYPERTENSION; MALIGNANT HYPERTHERMIA; NONHUMAN; QUANTITATIVE ANALYSIS; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; ANIMAL; DISEASE MODEL; DRUG ADMINISTRATION; DRUG EFFECT; HYPERTENSION; ORGAN SIZE; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; TREATMENT OUTCOME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BODY WEIGHT; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; HEMODYNAMICS; HYPERTENSION; MALE; ORGAN SIZE; PATIENT COMPLIANCE; RATS; RATS, INBRED SHR; TETRAZOLES; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

EID: 47749141482     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31815720a9     Document Type: Article

References (28)

1. Murray CJL, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet 1997;349:1269-76.
2. Bonow RO, Smaha LA, Smith SC Jr, et al. World heart day 2002: the international burden of cardiovascular disease: responding to the emerging global epidemic. Circulation 2002;106:1602-5.
3. Kannel WB. Blood pressure as a cardiovascular risk factor: prevention and treatment. JAMA 1996;275:1571-6.
4. Frohlich ED. Fibrosis and ischemia: the real risks in hypertensive heart disease. Am J Hypertens 2001;14(6 Pt 2):194S-9S.
5. Frohlich ED. Recent advances in hypertension, stroke, and cardiorenal disease. Curr Opin Cardiol 2005;20:258-63.
6. Veterans administration study group on antihypertensive agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressure averaging 115 through 129 mm Hg. JAMA 1967;202:1028-34.
7. Veterans administration study group on antihypertensive agents. Effects of treatment on morbidity in hypertension: II. Results in patients with diastolic blood pressure averaging 90 through 114 mm Hg. JAMA 1970;213:1143-52.
8. Cushman WC, Ford CE, Cutler JA. Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens 2002;4:393-404.
9. Chobanian AV, Bakris GL, Black HR, et al; and the National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003;42:1206-52.
10. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75.
11. Krousel-Wood M, Thomas S, Muntner P, et al. Medication adherence: a key factor in achieving blood pressure control and good clinical outcomes in hypertensive patients. Curr Opin Cardiol 2004;19:357-62.
12. Fields LE, Burt VL, Cutler JA, et al. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension 2004;44:398-404.
13. Turnbull F. Managing cardiovascular risk factors: the gap between evidence and practice. PloS Med 2005;2:e131-2.
14. Ono H, Ono Y, Frohlich ED. ACE inhibition prevents and reverses L-NAME-exacerbated nephrosclerosis in spontaneously hypertensive rats. Hypertension 1996;27:176-83.
15. Ishise S, Pegram B, Yamamoto Y, et al. Reference sample microsphere method: cardiac output and blood flows in conscious rat. Am J Physiol Heart Circ Physiol 1980;239: H443-9.
16. Kaneko K, Susic D, Nunez E, et al. Losartan reduces cardiac mass independent of pressure and hemodynamic changes. J Hypertens 1996;14:645-53.
17. Susic D, Nunez E, Hosoya K, et al. Coronary hemodynam-ics in aging spontaneously hypertensive (SHR) and normo-tensive Wistar-Kyoto (WKY) rats. J Hypertens 1998;16:231-7.
18. Susic D, Varagic J, Frohlich ED. Pharmacologic agents on cardiovascular mass, coronary dynamics, and collagen in aged spontaneously hypertensive rats. J Hypertens 1999;17:1209-15.
19. Armitage P, Berry G. Statistical methods in medical research, 3rd ed. Oxford: Blackwell Scientific; 1994.
20. Harmon G, Lefante J, Krousel-Wood MA. Overcoming barriers: the role of providers in improving patient adherence to antihypertensive medications. Curr Opin Cardiol 2006;21:310-5.
21. Krousel-Wood MA, Muntner P, Jannu A, et al. Reliability of a medication adherence measure in an outpatient setting. Am J Med Sci 2005;330:128-33.
22. Hawkshead J, Krousel-Wood MA. Techniques for measuring medication adherence in hypertensive patients in outpatient settings: advantages and limitations. Dis Manag Health Outcomes 2007;15:109-18.
23. Vaskonen T, Mervala E, Krogerus L, et al. Cardiovascular effects of chronic inhibition of nitric oxide synthesis and dietary salt in spontaneously hypertensive rats. Hypertens Res 1997;20:183-92.
24. Varagic J, Jerkic M, Jovovic D, et al. Regional hemody-namics after chronic nitric oxide inhibition in spontaneously hypertensive rats. Am J Med Sci 2000;320:171-6.
25. Li JS, Deng LY, Grove K, et al. Comparison of effects of endothelin antagonism and angiotensin-converting enzyme inhibition on blood pressure and vascular structure in spontaneously hypertensive rats treated with N omega-nitro-L-arginine methyl ester. Correlation with topography of vascular endothe-lin-1 gene expression. Hypertension 1996;28:188-95.
26. Zhou X, Frohlich ED. Differential effects of antihyperten-sive drugs on renal and glomerular hemodynamics and injury in the chronic nitric-oxide-suppressed rat. Am J Nephrol 2005;25:138-52.
27. Sever PS, Poulter NR. Blood pressure reduction is not the only determinant of outcome. Circulation 2006;111:2754-63.
28. Elliott WJ, Jonsson MC, Black HR. It is not beyond the blood pressure; It is the blood pressure. Circulation 2006;111:2763-72.